CA-SNORKEL-AI
18.1.2023 15:01:47 CET | Business Wire | Press release
Snorkel AI, the data-centric AI platform company, today announced record 2022 business momentum, led by triple-digit customer growth. New customer additions included BNY Mellon, Black Swan Data, Georgetown University's Center for Security and Emerging Technology (CSET), and Pixability. Snorkel AI also added five out of the top ten US banks to its customer portfolio and expanded its roster to include a number of government agencies and Fortune 500 companies across financial services, insurance, pharma and healthcare, manufacturing and retail industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118005384/en/
Snorkel AI Heads Into 2023 With Record Momentum and Growth (Graphic: Business Wire)
Enterprise data science and machine learning teams use Snorkel Flow, the company’s flagship AI platform powered by programmatic labeling, to accelerate AI application development by 10-100x. Organizations achieve hundreds of thousands to over million dollars in return on investment per project, and unlock net-new use cases for NLP, document processing, automation, analytics, and more blocked by manual labeling.
“The rate of progress in AI is accelerating, especially with foundation models,” said Alex Ratner, CEO and co-founder, Snorkel AI. “However, more enterprises than ever before are effectively blocked by the training data needed to adapt models for their specific use cases and production quality requirements. With our data-centric AI platform, we bridge the gap between enterprise AI and the latest innovations. Our market leadership and growth are clear indicators of the value this unlocks for our customers.”
Snorkel AI continued to innovate in 2022 by announcing the general availability of Snorkel Flow. The company also added a number of data-centric AI capabilities designed to accelerate enterprise AI development with automated labeling, efficient collaboration between data scientists and subject matter experts, and rapid, model-guided iteration.
- Data-centric Foundation Model Development: Workflows to fine-tune foundation models or large language models and use them to build smaller, specialized models deployable for complex, performance-critical enterprise use cases.
- Continuous Model Feedback: Automated model training and integrated analysis to provide near real-time guidance when developing training data.
- Cluster View: Instant creation of embedding-based clusters and auto-generated cluster labeling functions to quickly turn a massive unlabeled dataset into high-quality training data.
- New Studio: Support for a wide range data types and ML tasks such as text and document classification and extraction, PDF and conversational AI pipelines, sequence tagging, and more.
Additional 2022 highlights included:
- Expanded Partnership Ecosystem: Snorkel AI deepened partnerships across the enterprise AI ecosystem including Microsoft Azure AI Services, Google BigQuery and Vertex AI, Snowflake, Aimpoint Digital, Four Inc. and more.
- Hosted Largest Data-Centric AI Conference: Future of Data-Centric AI 2022 brought together thousands of leaders of data science and analytics teams, AI/ML practitioners, researchers, and students. The three-day event featured over 50 sessions from Apple, AstraZeneca, CIA, Capital One, Comcast, Databricks, Ford, Google, JPMorgan Chase, Meta, NVIDIA, Orange, State Farm, and more.
- Published Breakthrough Research: Snorkel AI Research published over 30 papers at NeurIPS, ICLR, ACL and more with academic partners at Brown University, Stanford University, University of Washington, and University of Wisconsin-Madison. The research team also contributed to major initiatives such as the WRENCH benchmark and BigScience advancing the state-of-the-art for data-centric AI.
- Received Industry and Analyst Recognition: Snorkel AI was named a 2022 Cool Vendor in their AI Core Technologies report and ranked in CBInsights AI 100: Most Promising AI Startups 2022. The company was also recognized by VentureBeat for their AI innovation award for Applied AI. Additionally, Snorkel AI was featured in WingVC: Top 30 Enterprise Tech and CRN: Top 10 Hottest AI Startups and Emerging Vendors lists.
About Snorkel AI
Founded by a team spun out of the Stanford AI Lab, Snorkel AI makes AI application development fast and practical by unlocking the power of machine learning without the bottleneck of manually-labeled training data. Snorkel Flow is the first data-centric AI platform powered by programmatic labeling. Backed by Addition, Greylock, GV, In-Q-Tel, Lightspeed Venture Partners and funds and accounts managed by BlackRock, the company is based in Palo Alto. For more information on Snorkel AI, please visit: https://www.snorkel.ai/ or follow @SnorkelAI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005384/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom